Tony Hagen

PARP Inhibitors Continue to Show Promise in Ovarian Cancer

November 29, 2017

As PARP inhibitors continue to improve outcomes in patients with ovarian cancer, they may one day be moved into the frontline treatment setting, said Susana M. Campos, M.D., a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School.

New CAR T-Cell Therapy Comes With a Hefty Price Tag

August 31, 2017

The newly approved CAR T-cell therapy, Kymriah (tisagenlecleucel), is being put on the market with a price tag of $475,000 for a single infusion, which is within the range that oncologists predicted.

What’s Next for Drug Price Reforms in Oncology?

July 19, 2017

“If you locked everybody in a room for a week, I think we could come up with something that everybody would be comfortable with,” said Blase Polite, M.D., a co-author of the statement, and immediate past chair of ASCO’s government relations committee.

Expert Panel Agrees: Drug Price Reform Is Much Needed

June 19, 2017

Reforms are needed high up within the drug distribution chain, concluded a panel of pharmaceutical professionals at the Oncology Market Access & Pricing conference held in Philadelphia this week by eyeforpharma.